Written question – Lowering of the reporting threshold for beneficiaries active in primary agricultural production to EUR 10 000 per calendar year – E-001598/2025

Source: European Parliament

Question for written answer  E-001598/2025
to the Commission
Rule 144
Christine Schneider (PPE)

As soon as the amount of tax relief reaches EUR 10 000 for the 2024 calendar year, beneficiaries must submit a multi-page tax declaration. These declarations can be over 60 pages long. The lowering of the reporting threshold to EUR 10 000 per calendar year affects producers who are active in primary agricultural production and in fisheries and aquaculture.

  • 1.Why has the Commission lowered the reporting threshold from EUR 100 000 to EUR 10 000?
  • 2.Under what conditions can the reporting threshold be raised back to the original EUR 100 000?

Submitted: 22.4.2025

Last updated: 30 April 2025

MOTION FOR A RESOLUTION on the draft Commission implementing decision authorising the placing on the market of products containing, consisting of or produced from genetically modified soybean MON 87705 × MON 87708 × MON 89788 pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council – B10-0244/2025

Source: European Parliament

Committee on the Environment, Climate and Food Safety
Members responsible: Anja Hazekamp, Martin Häusling, Biljana Borzan, Sirpa Pietikäinen

B10‑0244/2025

European Parliament resolution on the draft Commission implementing decision authorising the placing on the market of products containing, consisting of or produced from genetically modified soybean MON 87705 × MON 87708 × MON 89788 pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council (D105678/03 – 2025/2647(RSP))

The European Parliament,

 having regard to the draft Commission implementing decision authorising the placing on the market of products containing, consisting of or produced from genetically modified soybean MON 87705 × MON 87708 × MON 89788 pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council (D105678/03),

 having regard to Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modified food and feed[1], and in particular Article 7(3) and Article 19(3) thereof,

 having regard to the vote of the Standing Committee on Plants, Animals, Food and Feed referred to in Article 35 of Regulation (EC) No 1829/2003, on 28 February 2025, at which no opinion was delivered,

 having regard to Article 11 of Regulation (EU) No 182/2011 of the European Parliament and of the Council of 16 February 2011 laying down the rules and general principles concerning mechanisms for control by Member States of the Commission’s exercise of implementing powers[2],

 having regard to the opinion adopted by the European Food Safety Authority (EFSA) on 2 April 2020, and published on 18 May 2020[3],

 having regard to its previous resolutions objecting to the authorisation of genetically modified organisms (‘GMOs’)[4],

 having regard to Rule 115(2) and (3) of its Rules of Procedure,

 having regard to the motion for a resolution of the Committee on the Environment, Climate and Food Safety,

A. whereas on 11 September 2015, Monsanto Europe S.A./N.V. on behalf of Monsanto Company, based in the United States, submitted to the national competent authority of the Netherlands an application for the placing on the market of foods, food ingredients and feed containing, consisting of or produced from genetically modified soybean MON 87705 × MON 87708 × MON 89788 (‘the GM soybean’), in accordance with Articles 5 and 17 of Regulation (EC) No 1829/2003 (‘the application’). The application also covered the placing on the market of products containing or consisting of the GM soybean for uses other than food and feed, with the exception of cultivation;

B.  whereas on 2 April 2020, EFSA adopted a favourable opinion on the GM soybean, which was published on 18 May 2020; whereas EFSA had considered all the questions and concerns raised by the Member States in the context of the consultation with the national competent authorities, as provided for in Article 6(4) and Article 18(4) of Regulation (EC) No 1829/2003;

C. whereas EFSA was, however, not able to finalise the risk assessment and to conclude on the safety of the GM soybean due to the absence of a 90-day study on the GM soybean and the absence of a post-market monitoring plan taking into consideration the altered fatty acid profile of the GM soybean stack;

D.  whereas on 3 October 2024, EFSA adopted a statement, which was published on 28 October 2024, complementing its scientific opinion of 2 April 2020, based on the additional data provided by the applicant[5], EFSA concluded that the GM soybean, as described in the application, is as safe as its conventional counterpart and the tested non-genetically modified soybean reference varieties with respect to its potential effects on human and animal health and the environment. EFSA also concluded that the consumption of the GM soybean does not represent a nutritional concern;

E. whereas the GM soybean has been modified to be tolerant to glyphosate-based and dicamba herbicides and to alter its fatty acid profile;

Lack of assessment of the complementary herbicide

F. whereas Commission Implementing Regulation (EU) No 503/2013[6] requires an assessment of whether the expected agricultural practices affect the outcome of the studied endpoints; whereas, according to that Implementing Regulation, this is especially relevant for herbicide-tolerant plants;

G. whereas the vast majority of GM crops have been genetically modified to be tolerant to one or more ‘complementary’ herbicides which can be used throughout the cultivation of the GM crop, without killing the crop, as would be the case with a non-herbicide-tolerant crop; whereas a number of studies show that herbicide-tolerant GM crops lead to an increased use of complementary herbicides, in large part because of the emergence of herbicide-tolerant weeds[7];

H. whereas herbicide-tolerant GM crops lock farmers into a weed management system that is largely or entirely dependent on herbicides; whereas heightened reliance on complementary herbicides on farms planting the GM crops accelerates the emergence and spread of weeds resistant to those herbicides, thereby triggering the need for even more herbicide use, a vicious circle known as ‘the herbicide treadmill’;

I. whereas the adverse impacts stemming from excessive reliance on herbicides will lead to the deterioration of soil health, water quality and above and below ground biodiversity, and will also lead to increased human and animal exposure, potentially also via increased herbicide residues in food and feed;

J.  whereas dicamba is highly volatile, meaning that once applied, it is prone to move into the air and then drift on the wind until it falls to the ground, exposing people and non-target plants, vines, trees and shrubs to potential and serious damage, especially when exposure occurs over several years;

K. whereas a 2020 study by United States government scientists, published in the peer-reviewed journal International Journal of Epidemiology, found that heavy use of dicamba increased the risk of developing liver and intrahepatic bile duct cancers among applicators;

L. whereas the 2020 study states that approval of GM dicamba-resistant crops is expected to lead to increased agricultural use of dicamba in the years to come[8] and the Heartland Health Research Alliance’s Pesticide Use Data System confirms that that is the case, with dicamba use up 10-fold in the Midwest of the United States compared to a decade ago[9];

M. whereas questions concerning the carcinogenicity of glyphosate remain; whereas EFSA concluded in November 2015 that glyphosate was unlikely to be carcinogenic and the European Chemicals Agency concluded in March 2017 that no classification was warranted; whereas, on the contrary, in 2015, the International Agency for Research on Cancer, the specialised cancer agency of the World Health Organization, classified glyphosate as a probable carcinogen for humans; whereas a number of recent peer-reviewed scientific studies confirm the carcinogenic potential of glyphosate[10];

N. whereas a peer-reviewed study found that glyphosate accumulates in GM soybeans, with a corresponding negative impact on nutritional composition compared with non-GM soybeans[11]; whereas a pilot project carried out in Argentina found surprisingly high levels of glyphosate residues on GM soybeans[12];

O. whereas in GM plants, the way in which complementary herbicides are broken down by the plant, and the composition, and thus toxicity, of the break-down products (‘metabolites’) may be driven by the genetic modification itself[13];

P. whereas assessment of herbicide residues and metabolites found on GM plants is considered outside the remit of the EFSA Panel on GMOs and is therefore not undertaken as part of the authorisation process for GMOs;

Ensuring a global level playing field and upholding the Union’s international obligations

Q. whereas the cultivation of the GM soybean is not allowed in the Union;

R. whereas the conclusions of the Strategic Dialogue on the Future of EU Agriculture[14] call on the Commission to reassess its own approach to market access for agri-food imports and exports, given the challenge of diverging standards of the Union and its trading partners; whereas fairer trade relations consistent with goals for healthy food and a healthy environment, globally, were one of the main demands of the farmers during the demonstrations of 2023 and 2024;

S. whereas a 2017 report by the United Nations’ (UN) Special Rapporteur on the right to food found that, particularly in developing countries, hazardous pesticides have catastrophic impacts on health[15]; whereas the UN Sustainable Development Goal (‘UN SDG’) Target 3.9 aims to substantially reduce by 2030 the number of deaths and diseases caused by hazardous chemicals and air, water and soil pollution and contamination[16];

T. whereas the Kunming-Montreal Global Biodiversity Framework (‘Kunming-Montreal Framework’), agreed at the COP15 of the United Nations Convention on Biological Diversity (‘UN CBD’) in December 2022, includes a global target to reduce the risk of pesticides by at least 50 % by 2030[17];

U. whereas Regulation (EC) No 1829/2003 states that GM food or feed must not have adverse effects on human health, animal health or the environment, and requires the Commission to take into account any relevant provisions of Union law and other legitimate factors relevant to the matter under consideration when drafting its decision; whereas such legitimate factors should include the Union’s obligations under the UN SDGs and the UN CBD;

V. whereas Union authorisation of the GM soybean would not be consistent with international commitments on pesticide reduction[18], given the increased human and environmental exposure to herbicides in countries which grow herbicide-tolerant GM crops, along with the potentially serious associated health outcomes;

W. whereas deforestation is a major cause of biodiversity decline; whereas emissions from land use and land use change, mostly due to deforestation, are the second biggest cause of climate change after the burning of fossil fuels[19]; whereas the Paris Climate Agreement and the Strategic Plan for Biodiversity 2011-2020 adopted under the UN CBD and the Aichi Biodiversity Targets promote sustainable forest management, protection and restoration efforts[20]; whereas UN SDG 15 includes the target of halting deforestation by 2020[21]; whereas forests play a multifunctional role that supports the achievement of most UN SDGs[22];

X. whereas forest fires in the Amazon are driven by high levels of deforestation; whereas in a 2019 communication the Commission set out its ambition to protect and restore the world’s forests[23]; whereas the global protection of biodiversity, including forests, is a key objective of the EU Biodiversity Strategy[24];

Y. whereas soya production is a key driver of deforestation in the Amazon, Cerrado and Gran Chaco forests in South America; whereas 97 % of soya cultivated in Brazil and 100 % of soya cultivated in Argentina is GM soya[25];

Z. whereas an analysis by the Commission found that soya has historically been the Union’s number one contributor to global deforestation and related emissions, accounting for nearly half of the deforestation embodied in all Union imports[26];

Reducing dependency on imported feed

AA. whereas one of the lessons from the COVID-19 crisis and the still ongoing war in Ukraine is the need for the Union to end the dependencies on some critical materials; whereas in her mission letter to Commissioner Christophe Hansen, Commission President Ursula von der Leyen asks him to look at ways to reduce imports of critical commodities[27];

AB. whereas trade agreements incentivise imports to the Union of food and animal feed containing, consisting of or produced from GMOs; whereas Brazil and Argentina are among the world’s top GMO producers and pesticide users, including GMOs and pesticides banned in the Union for health or environmental reasons;

Undemocratic decision-making

AC. whereas, in its eighth term, Parliament adopted a total of 36 resolutions objecting to the placing on the market of GMOs for food and feed (33 resolutions) and to the cultivation of GMOs in the Union (three resolutions); whereas, in its ninth term, Parliament adopted 38 objections to placing GMOs on the market and has adopted another 10 resolutions objecting to placing GMOs on the market already in the current tenth term;

AD. whereas despite its own acknowledgement of the democratic shortcomings, the lack of support from Member States and the objections of Parliament, the Commission continues to authorise GMOs;

AE. whereas no change of law is required for the Commission to be able not to authorise GMOs when there is no qualified majority of Member States in favour in the Appeal Committee[28];

AF. whereas the vote on 28 February 2025 of the Standing Committee on Plants, Animals, Food and Feed referred to in Article 35 of Regulation (EC) No 1829/2003 delivered no opinion, meaning that the authorisation was not supported by a qualified majority of Member States; 

1. Considers that the draft Commission implementing decision exceeds the implementing powers provided for in Regulation (EC) No 1829/2003;

2. Considers that the draft Commission implementing decision is not consistent with Union law, in that it is incompatible with the aim of Regulation (EC) No 1829/2003, which is, in accordance with the general principles laid down in Regulation (EC) No 178/2002 of the European Parliament and of the Council[29], to provide the basis for ensuring a high level of protection of human life and health, animal health and welfare, and environmental and consumer interests, in relation to GM food and feed, while ensuring the effective functioning of the internal market;

3. Calls on the Commission to withdraw its draft implementing decision and to submit a new draft to the committee;

4. Calls on the Commission, in line with the One Health approach, not to authorise herbicide-tolerant GM crops, as it would lead to increased use of complementary herbicides and therefore increased risks to biodiversity, food safety and workers’ health;

5. Highlights, in this regard, that authorising the import for food or feed uses of any GM plant which has been made tolerant to herbicides is inconsistent with the Union’s international commitments under, inter alia, the UN SDGs and the UN CBD, including the recently adopted Kunming-Montreal Framework[30];

6. Expects the Commission, as matter of urgency, to deliver on its commitment to come forward with a proposal to ensure that hazardous chemicals banned in the Union are not produced for export, and on its commitment to ensure reciprocity by better aligning our domestic production standards with those applied to imports, notably for pesticides;

7. Calls on the Commission to ensure convergence of standards between the Union and its partners in free trade agreement negotiations, in order to meet Union safety standards;

8.  Welcomes the fact that the Commission finally recognised, in a letter of 11 September 2020 to Members, the need to take sustainability into account when it comes to authorisation decisions on GMOs[31]; expresses its deep disappointment, however, that, since then the Commission has continued to authorise GMOs for import into the Union, despite continued objections by the Parliament and a majority of Member States voting against;

9. Urges the Commission, again, to take into account the Union’s obligations under international agreements, such as the Paris Climate Agreement, the UN CBD and the UN SDGs; reiterates its call for draft implementing acts to be accompanied by an explanatory memorandum explaining how they uphold the principle of ‘do no harm’[32];

10. Instructs its President to forward this resolution to the Council and the Commission, and to the governments and parliaments of the Member States.

 

Iceland: Sidekick Health Secures €35 Million Venture Debt from EIB to Accelerate R&D and Global Expansion

Source: European Investment Bank

  • The European Investment Bank (EIB) has signed a €35 million venture debt facility with Sidekick Health, a leading digital health and therapeutics company operating across Europe and the US.
  • The funding will accelerate Sidekick’s therapy development and AI-driven platform innovation across multiple chronic and specialty care areas.
  • The R&D-focused facility is backed by the European Commission’s InvestEU initiative and complemented by a €7M capital injection from existing and new investors to accelerate Sidekick’s commercial growth.

The European Investment Bank (EIB) and Sidekick Health — a global leader in integrated digital health and therapeutics — today announced the signing of a €35 million venture debt facility, backed by a dedicated life science venture debt window of the European Commission’s InvestEU programme. It provides Sidekick with dedicated capital to accelerate R&D activities, expand its digital therapeutics portfolio, enhance AI capabilities, and strengthen its data and platform infrastructure — delivering scalable, secure, and impactful solutions for patients, payers, and pharmaceutical partners worldwide. The agreement represents the EIB Group’s first venture debt transaction in Iceland, where Sidekick is headquartered.

In parallel, Sidekick closed an additional €7M growth-focused financing, reflecting strong investor confidence and providing additional capital to scale its commercial footprint and strategic partnerships.

At the signing ceremony today in Luxembourg, Tryggvi Thorgeirsson, MD, MPH, CEO and Co-Founder of Sidekick Health, commented:

“This strategic financing from the EIB enables us to double down on our mission to improve and save lives by digitizing care. It strengthens our ability to invest in R&D, therapy development, and AI, while focusing future equity on scaling our commercial impact. Together with the strong backing of our investors, our diversified funding strategy — now including non-dilutive venture debt — positions Sidekick to accelerate innovation, deepen our partnerships, and continue transforming healthcare at scale.”

Thomas Östros, Vice-President of the EIB, said:

“The EIB has a solid track record in financing European med-tech companies through its venture debt instrument. The competitiveness of these companies is very important for our EU strategic autonomy. This is already the fifth InvestEU project in Iceland, building on a long tradition of EU-guaranteed funding for Icelandic projects.”

Sidekick partners with leading pharmaceutical companies, health insurers, and healthcare providers to deliver AI-enhanced digital health and therapeutics solutions across chronic and specialty care, including oncology, cardiovascular, metabolic, women’s health, and inflammatory conditions. The company’s platform has demonstrated improved patient outcomes and supported cost reduction in collaboration with partners, helping drive the shift toward personalized, proactive care.

EU Ambassador to Iceland Clara Ganslandt added:

“It was only in January last year, 2024, that Iceland’s participation in InvestEU was formally launched but we now already have five InvestEU projects in Iceland. That is certainly worth celebrating. The EU is committed to fuelling research and innovation and making use of impactful investments – in a world of increased global competition, it is in our common interest for Iceland and the European Union to work together. For three decades, since 1994, Icelandic organisations have been remarkably active, valued and successful participants in EU programmes, and Sidekick Health will certainly make this financing agreement a success.”

Background information  

EIB 

The European Investment Bank (ElB) is the long-term lending institution of the European Union, owned by its Member States. Built around eight core priorities, we finance investments that contribute to EU policy objectives by bolstering climate action and the environment, digitalisation and technological innovation, security and defence, cohesion, agriculture and bioeconomy, social infrastructure, high-impact investments outside the European Union, and the capital markets union.  

The EIB Group, which also includes the European Investment Fund (EIF), signed nearly €89 billion in new financing for over 900 high-impact projects in 2024, boosting Europe’s competitiveness and security.  

All projects financed by the EIB Group are in line with the Paris Climate Agreement, as pledged in our Climate Bank Roadmap. Almost 60% of the EIB Group’s annual financing supports projects directly contributing to climate change mitigation, adaptation, and a healthier environment.  

Fostering market integration and mobilising investment, the Group supported a record of over €100 billion in new investment for Europe’s energy security in 2024 and mobilised €110 billion in growth capital for startups, scale-ups and European pioneers. Approximately half of the EIB’s financing within the European Union is directed towards cohesion regions, where per capita income is lower than the EU average.

High-quality, up-to-date photos of our headquarters for media use are available here.

InvestEU

The InvestEU programme provides the European Union with crucial long-term funding by leveraging substantial private and public funds in support of a sustainable economy. It helps generate additional investments in line with EU policy priorities, such as the European Green Deal, the digital transition and support for small and medium-sized enterprises. InvestEU brings all EU financial instruments together under one roof, making funding for investment projects in Europe simpler, more efficient and more flexible. The programme consists of three components: the InvestEU Fund, the InvestEU Advisory Hub, and the InvestEU Portal. The InvestEU Fund is implemented through financial partners who invest in projects using the EU budget guarantee of €26.2 billion. This guarantee increases their risk-bearing capacity, thus mobilising at least €372 billion in additional investment.

Sidekick Health

Sidekick Health is a digital health innovation company offering a uniquely broad portfolio of digital health and therapeutic programs across oncology, cardiovascular, metabolic, women’s health, and inflammatory conditions. Our solutions engage and empower people to improve health outcomes and quality of life. Sidekick works with health insurers, including leading national US health plans, pharmaceutical companies, including half of the world’s top 10 life sciences companies, and develops fully regulated prescription digital therapeutics — prescribed by over 17,000 physicians — designed to improve patient outcomes, enhance clinical efficiency, and reduce the cost of care.

Study – Human exposome research: Potential, limitations and public policy implications – 30-04-2025

Source: European Parliament

This report examines the emerging field of exposomics, which studies the cumulative impact of environmental exposures on human health. It highlights the limitations of established environmental health research and advocates a more comprehensive approach. The report explores exposomics’ application in various sectors, including urban planning, chemical safety, climate adaptation, child health, workplace safety, clinical practice, and citizen empowerment. It emphasises the need for improved exposure assessments, integration of data, international collaboration, and sustainable data infrastructure. The report discusses the potential of artificial intelligence in advancing exposomics, and addresses ethical considerations for the field. Finally, the study outlines options for integrating exposomics into EU policies to improve public health, regulatory decision-making, and innovation. It highlights the opportunity to create a large-scale European Human Exposome Initiative to position the EU as a global innovation leader.

External author

Busquet, Francois; Downward, George; Hoek, Gerard; Miller, Gary; Peters, Susanne; Safarlou, Caspar; Sanciaume, Maurice; Vermeulen, Roel; Vlaanderen, Jelle; Vrijheid, Martine

Written question – Joint efforts to prevent and combat different forms of hatred against traditional national and linguistic minorities – E-001599/2025

Source: European Parliament

Question for written answer  E-001599/2025
to the Commission
Rule 144
Loránt Vincze (PPE)

A young man was recently attacked with a knife for using a minority language, Hungarian, in Bratislava, Slovakia[1]. A group of young local supporters were beaten for speaking Hungarian in Cluj-Napoca, Romania[2]. Far from being isolated incidents, hate speech is present throughout Europe and it affects different communities from various regions. Hate speech and hate crimes targeting traditional national and linguistic minorities remain a serious concern in the EU. The Intergroup on Traditional Minorities, National Communities and Languages[3] has been informed of several such cases[4].

  • 1.How can the Commission improve its actions to prevent and combat hate speech and hatred targeting, in particular, traditional national and linguistic minorities, and ensure their effective support at EU level?
  • 2.As the Commission already pays particular attention to specific forms of hate speech and hate crime experienced by certain communities, would it consider focusing its attention on traditional national and linguistic minorities, who represent 10 % of the EU population?
  • 3.Would the Commission consider including the effort to combat hate speech and hate crimes against traditional minorities in the work programme of the High-Level Group on combating hate speech and hate crime?

Submitted: 22.4.2025

  • [1] spectator.sme.sk/politics-and-society/c/man-attacked-by-knife-in-bratislava-supposedly-for-hungarian-origin.
  • [2] www.mikoimre.ro/en/young-man-attacked-by-cluj-ultras-for-speaking-hungarian.
  • [3] www.europarl.europa.eu/meps/en/intergroup/details/7895/Intergroup%20on%20Traditional%20Minorities,%20National%20Communities%20and%20Languages.
  • [4] For further cases of hate crime and hate speech committed against traditional national and linguistic minorities see: https://minoritymonitor.eu/.
Last updated: 30 April 2025

Written question – Israeli legislation on registration and visa issuance for international NGOs – E-001532/2025

Source: European Parliament

Question for written answer  E-001532/2025/rev.1
to the Vice-President of the Commission / High Representative of the Union for Foreign Affairs and Security Policy
Rule 144
Cecilia Strada (S&D), Marco Tarquinio (S&D), Leoluca Orlando (Verts/ALE), Ilaria Salis (The Left), Rudi Kennes (The Left), Thijs Reuten (S&D), Nikos Pappas (The Left), Daniel Attard (S&D), Carola Rackete (The Left), Marc Botenga (The Left), Hanna Gedin (The Left), Jonas Sjöstedt (The Left), Evin Incir (S&D), Sandra Gómez López (S&D), Annalisa Corrado (S&D), Sandro Ruotolo (S&D), Pierre Jouvet (S&D), Marta Temido (S&D), Damien Carême (The Left), Marit Maij (S&D), Rima Hassan (The Left), Chloé Ridel (S&D), Alex Agius Saliba (S&D), Brando Benifei (S&D), Mounir Satouri (Verts/ALE), Jaume Asens Llodrà (Verts/ALE), Tilly Metz (Verts/ALE), Rasmus Nordqvist (Verts/ALE), Villy Søvndal (Verts/ALE), Mélissa Camara (Verts/ALE), Catarina Vieira (Verts/ALE), David Cormand (Verts/ALE), Tineke Strik (Verts/ALE), Majdouline Sbai (Verts/ALE), Benedetta Scuderi (Verts/ALE)

On 9 March 2025, new Israeli legislation on registration and visa issuance for international NGOs came into effect[1]. Both Israeli and international observers note that these provisions are aimed at denying access to international NGOs providing assistance to the Palestinian population[2]. Visa requirements are now purposely vague and thus highly discretionary, with the registration applications of international NGOs being evaluated solely by government officials. Consequently, this legislation risks becoming a tool for silencing government critics.

The Knesset is also considering further financial and operational restrictions for internationally funded NGOs[3], including an 80 % tax on international donations and barring access to justice for NGOs relying on foreign funding.

These repressive policies will likely obstruct the delivery of humanitarian aid and welfare services to Palestinians. While the EU allocates EUR 1.5 billion for Palestinian assistance, Israel’s policies threaten the operations of many EU-funded humanitarian actors[4].

Taking into account Article 2 of the EU-Israel Association Agreement:

  • 1.Was the new Israeli legislation on international NGOs discussed at the latest EU-Israel Association Council meeting? If so, what was the outcome of the discussion?
  • 2.Will the Commission propose the suspension of the Association Agreement if international NGOs are forbidden access to the Occupied Palestinian Territories?

Supporters[5]

Submitted: 15.4.2025

  • [1] https://www.gov.il/he/pages/dec2542-2024
  • [2] Inter alia: https://gisha.org/en/ngos-in-israel-condemn-an-israeli-government-decision-designed-to-deny-registration-and-work-visas-to-international-humanitarian-organizations/; https://www.focsiv.it/wp-content/uploads/2025/03/Dossier-Informativo-questione-registrazione-in-Israele.pdf; https://reliefweb.int/report/occupied-palestinian-territory/implementation-new-israeli-ngo-registration-and-visa-regulations
  • [3] S. Sokol, Ministers advance bill levying 80% tax on foreign state funding of Israeli NGOs, The times of Israel, 16 February 2025, https://www.timesofisrael.com/ministers-vote-to-back-bill-levying-80-tax-on-foreign-state-funding-of-israeli-ngos/
  • [4] https://www.consilium.europa.eu/en/policies/eu-humanitarian-support-to-palestinians/
  • [5] This question is supported by Members other than the authors: Cristina Guarda (Verts/ALE), Matjaž Nemec (S&D)

Written question – Aviation safety and implementation of EU rules – E-001606/2025

Source: European Parliament

Question for written answer  E-001606/2025
to the Commission
Rule 144
Nikolaos Anadiotis (NI)

Critical issues for flight safety in Greece are being raised due to serious malfunctions in the ‘non-operational’ aircraft collision control and warning system, especially in the terminal area of​ Athens airport, which are being denounced by the Greek Association of Air Traffic Controllers (AATC).[1]

The AATC is sounding the alarm due to outdated surveillance and communications equipment, inadequate staffing and other dangerous – mainly during periods of increased air traffic – operational and working conditions. The above conditions potentially jeopardise the country’s compliance with Regulation (EU) 2018/1139,[2] Regulation (EU) 139/2014[3] and Regulation (EU) 965/2012,[4] which require high safety standards in civil aviation and the proper functioning of air traffic systems.

In light of the above:

  • 1.How does the Commission assess the complaints regarding the operational status of the air collision avoidance system in Greece?
  • 2.Has it carried out (or does it intend to carry out), through the European Aviation Safety Agency (EASA) and other competent bodies, an updated review of the status of the National Air Traffic Systems in Member States with identified gaps, such as, for example, Greece?
  • 3.What measures does it intend to put in place to ensure Greece’s full compliance with the EU aviation safety framework and the modernisation/functionality of air traffic systems?

Submitted: 22.4.2025

  • [1] https://www.flash.gr/epistoli-vomva-ton-elegkton-enaerias-kykloforias-tyflo-to-systima-proeidopoiisis-sygkroysis-982188?utm_source=chatgpt.com.
  • [2] https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex:32018R1139
  • [3] https://eur-lex.europa.eu/eli/reg/2014/139/oj/eng
  • [4] https://eur-lex.europa.eu/eli/reg/2012/965/oj/eng
Last updated: 30 April 2025

Written question – Closure of mines and lignite-fired power stations in Western Macedonia: a great cause of suffering for the people – E-001603/2025

Source: European Parliament

Question for written answer  E-001603/2025
to the Commission
Rule 144
Lefteris Nikolaou-Alavanos (NI)

Heightened competition between the EU and Russia and competitive planning by the US are paving the way for further increases in the cost of energy and basic commodities. The implementation of the EU’s green strategy is also marked by the closure, by the Greek Government and Public Power Corporation, of the Meliti and Megalopoli coal-fired power stations and the planned closure of the one in Agios Dimitrios and of the mines that supply them. Power plants harnessing a local fuel, lignite, are being replaced by plants running on imported natural gas. This is depriving the people of access to cheap electricity, while fostering unemployment in Western Macedonia and jeopardising national energy security.

The Commission’s action plan for ‘cheaper natural gas imports’ increases dependence on LNG from the US, which is more expensive, while guaranteeing lower relative energy prices for large industrial groups.

Can the Commission say:

  • 1.How does it view the fact that the ‘green’ energy strategy pursued by the EU and national governments is determined by the requirements and interests of business groups?
  • 2.What view does it take of the fact that ending dependence on Russian gas, abandoning cheap domestic lignite and shifting towards more expensive LNG from the US and the measures to increase the share of renewable energy sources under the conditions of the ‘liberalised market’ only result in further increases in costs for ordinary households, exploitative labour conditions for workers in the sector and a blight on the people of Western Macedonia?

Submitted: 22.4.2025

Last updated: 30 April 2025

Written question – Austria suspending family reunification – E-001617/2025

Source: European Parliament

Question for written answer  E-001617/2025
to the Commission
Rule 144
Thomas Waitz (Verts/ALE), Lena Schilling (Verts/ALE), Erik Marquardt (Verts/ALE)

Austria plans to introduce a blanket suspension on family reunification for third-country nationals, in violation of Directive 2003/86/EC on the right to family reunification. In a letter of 4 March 2025 to the Commission, the Austrian Minister of the Interior says that the reunification procedures jeopardise the functioning of the Austrian state’s institutions and its most important public services in particular. Austria thus plans to apply Article 72 of the Treaty on the Functioning of the European Union.

  • 1.Does the Commission consider the Austrian announcement to be in line with EU law and, if so, how?
  • 2.If the Austrian announcement is not in conformity with EU law, how not?
  • 3.How did the Commission respond to the letter from the Austrian Minister of the Interior and what steps will it take next?

Submitted: 23.4.2025

Last updated: 30 April 2025

Written question – Support for the Ionian Islands in relation to landslides – E-001597/2025

Source: European Parliament

Question for written answer  E-001597/2025
to the Commission
Rule 144
Georgios Aftias (PPE)

Coastal areas in the European Union are in a vulnerable and dynamic situation due to human intervention and natural processes, which change their morphology, but also due to the advantages they bring at a social and economic level. They are greatly affected by coastal soil erosion, as well as by wave activity. The Ionian Islands contribute significantly to trade, transport and tourism, offering a huge range of economic development and professional activity to Greek society.

According to a report by the Region of the Ionian Islands, signed by the Regional Governor, Mr. Ioannis Trepeklis, after long-term research and studies it has been established that the Ionian Islands region is particularly vulnerable to coastal erosion and the most prone to ongoing and strong seismic vibrations worldwide. The islands of Corfu, Kefalonia, Zakynthos and Lefkada are mentioned. The Ionian Islands Region is raising this issue with urgency, as solving the problem also requires immediate European intervention.

In view of the above:

  • 1.Will the Commission support the strengthening of the resilience of coastal areas with all financial means?
  • 2.Will the Commission finance national initiatives that contribute to the protection of the inhabitants of coastal areas from the effects caused by soil erosion?

Submitted: 22.4.2025

Last updated: 30 April 2025